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Abstract: Coxiella burnetii is an obligate intracellular pathogen and the causative agent of the 
zoonotic illness Q fever. With an infectious dose of 1-10 organisms, C. burnetii is one of the 
most infectious bacteria known. Formulations of killed whole-cell C. burnetii virulent strains has 
been shown to be effective when administered intramuscularly, intraperitoneally, and sub-
cutaneously, but has not been assessed using an intranasal route of inoculation that would also 
bring to bear the mucosal immune response. We hypothesized that intranasal immunization 
would be protective against subsequent challenge with live virulent C. burnetii. Using a guinea 
pig model, intranasal immunization with a mixture of killed whole-cell C. burnetii Nine Mile 
phase I combined with double mutant lethal toxin (DmLT) adjuvant. Booster immunizations 
were administered at 14 and 28 days. Sera was drawn for IgG titers prior to, and at 14, 28, and 56 
days following intranasal immunization. Analysis of sera indicates that a robust humoral 
response is elicited following intranasal immunization. Additionally, immunized guinea pigs that 
were subsequently challenged with virulent C. burnetii NMI did not develop significant clinical 
symptoms as measured by fever and weight loss when compared to animals receiving the mock 
immunization. Studies defining minimal immunization requirements, potential hypersensitivity 
response, and protective antigen profile using this physiologically relevant exposure route will 
aid us in defining a protective response to this unusual aerosol acquired pathogen. 
For the first 80 years following its discovery, C. burnetii could only be grown in a system 
providing live cells within which it would replicate. The relatively recent advent of cell free 
media has been a boon for C. burnetii research on many fronts. We noticed when infecting 
cultured cells using C. burnetii that had been repeatedly passaged in cell free defined acidified 
citrate cysteine media (ACCM-D), that the infectivity rates were lower than expected based on 
the number of genomes used to initiate the infection relative to C. burnetii that had been derived 
from infected cells. Infectious assays comparing C. burnetii from passages 1, 3, 5 and 10 
determined that by passage 10 the organism’s relative ability to infect cultured cells had 
decreased 2-logs. We hypothesized that molecular changes were occurring in these early 
passages that related to the ability of the bacteria to infect or grow within host cells at their 
normal rate. We initiated a “Reverse Evolution” approach to study the molecular changes that 
occur following serial passages in axenic media to determine what occurs when the stressors 
associated with C. burnetii’s typically intracellular lifestyle are removed. We found that the 
concentration of DotA and IcmX, two structural proteins of the Type IVB Secretion System, 
which is required for intracellular growth, were significantly reduced by passage 10. Mass spec 
analysis of passages 1, 3, and 5 also demonstrate changes between protein levels in subsequent 
passages analyzed. Expanded mass spec and RNAseq analysis to include passage 10, along with 
immunoblot analysis and genome sequencing of both early and longer-term passages will 
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Coxiella burnetii is an obligate intracellular bacterium in nature. It is the causative agent of 
the zoonotic illness Q fever [1]. Acute Q fever is characterized by mild flu-like symptoms 
including headache, fever, coughing, and myalgia. This  illness typically resolves on its own 
although in diagnosed cases, a 14-day course of doxycycline may be prescribed [2]. Chronic 
infections may also occur and are accompanied by symptoms that include endocarditis, 
hepatitis, or chronic fatigue syndrome [3, 4]. Treatment of chronic Q fever is more 
complicated and expensive, with an 18-24-month course of doxycycline and 
hydroxychloroquine being a typical treatment [5]. 
Coxiella burnetii undergoes a biphasic lifecycle composed of two morphological 
forms, the small cell variant (SCV) and the large cell variant (LCV) [6, 7].  The SCV is the 
environmentally stable form of the organism that infects eukaryotic host cells. Once within 
the host cell, C. burnetii remains within a cell derived vacuole that essentially follows the 
endocytic pathway to become a pathogen containing vacuole resembling a late endosome. 
These are referred to as the parasitophorus vacuole (PV). Within this vacuole, C. burnetii 
transforms into the replicative LCV form within 24-48 hours post infection. The LCV 
replicates within the PV while manipulating the host cell to provide the necessary nutrients, 
etc. for its survival and replication. After 6 days, depending on initial infection level, C. 
burnetii begins an asynchronous transformation back to the SCV form, and eventual cell lysis 
frees the infectious particles to repeat the process in new host cells [6, 8].  
 
In this dissertation, I sought to address two distinct questions associated with C. 




• Does intranasal inoculation using killed whole cell C. burnetii protect against 
subsequent challenge using live virulent C. burnetii? 
• What temporal gene expression and/or genetic changes may occur when the 
stressors of an intracellular environment are removed? 
 
The environmental stability, aerosol transmission, and an infectious dose of 1-10 
organisms [9] are historically of concern and has led C. burnetii to be classified by the 
Centers for Disease Control as a Class B Select Agent [10]. There is an existing commercial 
vaccine, Q-Vax, that uses killed whole cell C. burnetii, however, it is only available in 
Australia [2, 11-13]. The Q-Vax vaccine is very effective but causes a delayed type 
hypersensitivity (DTH) response at the site of injection in individuals with previous exposure 
to C. burnetii [14]. This results in the need to screen all individuals prior to receiving this 
vaccination [15]. As such, there is an ongoing need for a more suitable C. burnetii vaccine 
that removes the need for pre-screening. Whole cell killed formulations of virulent C. 
burnetii strains have been found to be effective following intramuscular, intraperitoneal, and 
subcutaneous immunization in various infectious challenge models [2]. However, analysis of 
an intranasal route of immunization for this aerosol acquired infection has not been tested. As 
such we sought to answer the following question:  
• Does intranasal inoculation using killed whole cell C. burnetii protect against 
subsequent virulent C. burnetii challenge?  
 
C. burnetii was initially discovered and continually cultivated in guinea pigs during 




cultured on typical bacterial growth media, although methods were soon 
developed/discovered whereby it could be cultivated to large numbers in embryonated 
chicken eggs [17]. Years later, the development of immortal tissue culture methods further 
advanced the availability of C. burnetii models for growth and physiologic research, but 
research with the organism was still restricted to the limitations of host-cell infections [18]. 
However, in 2009 a cell free media for growing C. burnetii in vitro,  Acidified Citrate 
Cysteine Media (ACCM), was developed allowing  research away from the host cell 
background to be performed [19]. When grown in eggs, tissue culture, or ACCM, i.e. outside 
of an animal host, a well-documented change occurs within the bacterial population [20-22]. 
When passaged in eggs, tissue culture, or ACCM, genetic mutations occur that results in a 
severely truncated LPS. Virulent, or phase I, C. burnetii possess a full-length 
lipopolysaccharide (LPS). The LPS mutant C. burnetii are referred to as phase II 
organisms/strains  [23-25]. As a result of this truncation, the C. burnetii are no longer able to 
evade the immune system in an animal host and are no longer virulent. However, these phase 
II organisms retain all of their ability to invade, survive, and grow within a host cell, making 
them an exceptional model of phase I C. burnetii in tissue culture infections and subsequent 
molecular analysis of pathogen-host cell molecular interactions [23, 24].  
When performing infections of eukaryotic cells with the model C. burnetii Nine Mile 
phase II (NMII) strain that had been serially passaged in ACCM several times, we observed 
what appeared to be a reduced number of infectious forming units relative to what was 
expected based on the number of organisms used for the infection. Preliminary analysis 




increase in the number of in vitro ACCM-D passages of the bacteria. This led us to pose the 
following questions: 
• What temporal gene expression changes may occur when the stressors of an 
























History of Coxiella 
Discovery 
 The first diagnosis of an unknown illness known as query or “Q” fever occurred 
in Australia. This unexplained illness was investigated by the physician Edward Derrick 
following periodic outbreaks of a febrile illness in abattoir workers. The symptoms of this 
illness were inconsistent with other known diseases, and the test results of patients 
suffering from this illness were negative for influenza, typhus, leptospirosis, and other 
common fever agents. Derrick was able to successfully passage the organism from the 
blood of infected patients to guinea pigs, but was unable to cultivate or visualize the 
organism by traditional means [1].  
 Derrick sent emulsified liver from an infected guinea pig to the prominent 
virologist MacFarlane Burnet after concluding that the pathogen was a virus. Burnet used 
the liver emulsion to infect animals and document their symptoms. Smears made from the 
enlarged spleens of infected mice showed intracellular organisms similar to Rickettsiae 
[16]. Based on these observations Derrick named the Q fever agent Rickettsia burneti 
[26].  
 Derrick began to look into the possibility that arthropods or other vectors were 
involved in R. burneti transmission. Concurrent with the studies in Australia, a lab in the 
United States was unknowingly looking into the same organism. The Rocky Mountain 
Laboratories (RML) in Montana, a part of the federal Dept. of Health Services, were 
investigating the epidemiology of Rocky Mountain Spotted Fever (RMSF) causative 




andersoni) were collected along Nine Mile Creek and allowed to feed on guinea pigs. 
These guinea pigs would then be monitored for fever as a symptom of any potential 
illness. Following one of these feedings, one of the guinea pigs developed a febrile illness 
that was transferable to healthy guinea pigs through blood transfusion. However, the 
symptoms displayed were not consistent with RMSF [28]. This organism was, for the 
time, named Nine Mile Agent (NMA) as they continued to study and characterize it. 
Herald Cox was assigned to assist in the characterization. He found that NMA could be 
passaged to guinea pigs from an infected guinea pig and could be passed through filters 
that typically retained bacteria, but not viruses [28]. 
 Cox sought to further understand this organism, which he initially called 
Rickettsia diaporica (Greek for “ability to pass through”) after initial tests of NMA fit the 
broad definitions used to classify Rickettsial species. Rolla Dyer, who was the director of 
the Public Health Service at the time, travelled to RML to verify research claims that 
were being made by Cox about R. diaporica. During Dr. Dyer’s time at RML he was 
accidentally infected with R. diaporica while handling infected guinea pigs and 
embryonated eggs. He used this opportunity to record details about his symptoms and 
also infected guinea pigs with the agent using his own blood [29]. Following Dyer’s 
publications, guinea pigs that had recovered from R. burneti (the Australian agent) 
challenge were found to have protective immunity against R. diaporica. Thus, it was Dr. 
Dyers accidental infection and subsequent publication that led to the connection between 





 An outbreak of Q fever during the course of World War II [32, 33] prompted new 
interest in C. burnetii research [34-36], and led RML researcher Cornelius Philip to 
suggest a single name for R. burneti and R. diaporica, as well as a new genus to separate 
this organism from other Rickettsiae sp. due to its unique characteristics. In honor of both 
Burnet and Cox the subgenus Coxiella was suggested with the species name burneti, 
which was later changed to burnetii [37]. 
Cultivation History and Development 
 The growth and cultivation of C. burnetii has changed greatly over the course of 
80 years and is summarized in Figure 1. When C. burnetii was first discovered it was 
only able to be passaged or maintained using infected animals, primarily guinea pigs [2, 
16, 17]. Attempts to cultivate the organism on other growth media were unsuccessful [1]. 
While this allowed researchers to study the infection and symptoms, it was impractical 
for long term cultivation and maintenance of C. burnetii as guinea pigs would eventually 
either recover and clear the organism or succumb to infection [16, 38]. While studying 
this organism at RML, Cox discovered he was able to grow C. burnetii in a tissue culture 
of minced embryonated eggs. This led to the subsequent discovery that embryonated eggs 
could be directly infected and used for larger scale cultivation of C. burnetii [17]. Yolk 
sacs of these infected eggs could be harvested and C. burnetii could be purified using 
differential and density gradient centrifugation [39]. While this was a far better method 
than passaging in guinea pigs, given the large quantities of C. burnetii produced there 
were safety concerns associated with yolk sac harvesting, as well as the time constraints 




Figure 1.  Timeline of C. burnetii Cultivation. Initial research involving C. burnetii was 
only done in animal models. Advancements in the cultivation of C. burnetii over time are 
demonstrated here (Timeline not drawn to scale). 
 
 The use of embryonic tissue culture was an appealing alternative to the previous 
methods of cultivation [18], and the advent of diverse and robust tissue culture methods 
has aided in C burnetii studies since their development in the late 1950s. Since that time, 
Coxiella burnetii has been shown to infect and grow in multiple mammalian cell lines 
[18] in vitro, as well as at least one tick cell line [40]. Cell culture infection was an 
advantageous development that allowed for both studies of the organism as well as 
propagation and isolation of C. burnetii using a variety of lysis and differential 
centrifugation methods. More recently, a methodology of C. burnetii isolation from 
infected cultures was developed where the organisms were driven toward the SCV form 
prior to bacterial harvest [18], allowing for the initiation of a more synchronous infection 
in subsequent studies [41]. While these methods showed improvement to previous 
methods, the requirement of separating C. burnetii from residual host cell debris 




 Over the years, researchers have sought the development of a host-cell free means 
to grow C. burnetii. One advancement toward this goal was the development of a media 
that allowed in vitro metabolic activity of purified C. burnetii. In this early metabolic 
media, a relatively minimal metabolic activity could be achieved relative to that observed 
in host cells [42]. However, advances in, and use of, this metabolic media revealed 
several of the lysosomal characteristics and physiologic properties of the parasitophorus 
vacuole (PV) where C. burnetii resides during infection [43, 44]. Based on these findings 
it was demonstrated that C. burnetii metabolism improved in conditions similar to those 
found within the PV. Macro-molecular synthesis of protein and nucleic acid was 
achieved in simple phosphate buffers when the pH was lowered to 4.5 and supplemented 
with amino acids and glucose [45, 46]. Proteins were synthesized [46] and secreted [47] 
for 24 hours post inoculation and DNA synthesis occurred for up to 15 hours [45] in this 
media. However, cell division did not occur. 
 These early metabolic media formulations were phosphate based, but in 2008 an 
improved metabolic media, designated complex Coxiella media (CCM), was developed 
that was citrate based in an effort to appropriately buffer the acidic pH required by C. 
burnetii during extended incubation [48]. The CCM media increased the metabolic 
activity of purified C. burnetii  substantially, yet bacterial replication was not detected 
[19]. Further studies and bioinformatic analysis of the C. burnetii genome revealed that 
C. burnetii is auxotrophic for several amino acids that were subsequently added to create 
Acidified Citrate Cysteine Medium (ACCM) [19, 48]. An increase in protein synthesis 
resulted, but C. burnetii replication remained elusive. Further gene expression and 




vs. cell culture growth suggested that C. burnetii possesses a cytochrome system similar 
to that of microaerophilic bacteria [19]. When C. burnetii was subsequently incubated in 
ACCM in microaerophilic conditions (2.5% oxygen), replication was achieved [19]. The 
growth in ACCM was shown to generally mimic the biphasic life cycle of C. burnetii, 
with the change from SCV to LCV followed by the conversion back to SCV after log 
growth, as observed in tissue culture infections [19]. This original ACCM contained 
complex ingredients such as RPMI media, yeast extract, and fetal bovine serum (FBS), 
potentially complicating downstream molecular analysis [19]. However, in 2011, a 
modification of the components in ACCM led to an updated media, ACCM-2, that did 
not contain Fetal Bovine Serum (FBS) [49]. The replication of C. burnetii in ACCM-2 
increased between 1 to 2 logs versus ACCM while the generation time was slightly 
decreased. In addition, with the development of ACCM-2 came the ability to prepare agar 
plates that could be utilized for the growth of C. burnetii colonies [49]. Bacterial numbers 
and generation times were further improved with the most recently developed media, 
ACCM-D [50]. ACCM-D is a fully nutritionally defined media with known amino acid 
concentrations [50, 51]. This defined media also allows researchers to take advantage of 
C. burnetii’s auxotrophy to generate plasmid systems that enable selection using non-
antibiotic methods to create stable genetic mutants [52]. Given the paucity of selectable 
antibiotic markers allowed in C. burnetii genetics this was a particularly important 
development.  






 Q fever is a zoonotic illness caused by the intracellular bacterium C. burnetii. It is 
found worldwide in the environment and has the ability to infect a broad range of 
organisms [2, 53]. Transmission of C. burnetii generally occurs when contaminated 
aerosols are inhaled following release from an infected organism. In humans these 
inhaled C .burnetii infect alveolar macrophages and initiate systemic infection as 
monocytes migrate from the lungs to other sites [8, 54]. C. burnetii is environmentally 
stable and has an infectious dose of only 1-10 organisms being required to initiate an 
infection [55]. The symptoms of C. burnetii vary greatly, but typically present as a mild 
flu-like illness. Severity of illness and presentation can vary from individuals who may be 
asymptomatic to those developing chronic infections where major organs, including the 
heart and liver, can be affected [2, 12].  
Acute illness 
The incubation period of Q fever ranges from 1 to 3 weeks and varies based on 
the dose of inoculum. Many Q fever cases are asymptomatic, and symptomatic illness 
most commonly presents as a self-limiting flu-like illness [2, 56, 57]. Patients typically 
experience an abrupt onset of fever, fatigue, chills, and headaches. The fever can reach 
104-105 F and peaks within 2-4 days before returning to normal between 5-14 days. 
Patients older than 40 years have been reported to have a longer duration of fever [2, 58]. 
When Q fever is left untreated the fever has been reported to last from anywhere between 




following the first phase there is a reappearance of the fever lasting from 1 to 19 days [2, 
56, 57, 59].  
 Pneumonia is a common complication associated with acute Q fever. Patients 
experiencing high fever frequently develop atypical pneumonia. This is often associated 
with fatigue, chills, myalgia, and sweats [60]. Hepatitis, myocarditis, pericarditis, and 
meningoencephalitis occur less frequently than pneumonia but have also been reported 
[2]. Acute or asymptomatic Q fever can also cause pregnancy complications that result in 
spontaneous abortions or placental abruptions [61-63]. The fatality rate associated with 
acute Q fever is less than one percent, indicating that the normal immune response is 
capable of eliminating the organism[64].  
 Diagnosis of acute Q fever is complicated by its flu-like symptoms, which closely 
resemble other infectious diseases, often leading to misdiagnosis [30, 56, 65-67]. In the 
majority of acute cases of Q fever, the leukocyte count remains in the normal range [6]. 
Because of this, serology is the primary method of confirmatory diagnosis. Indirect 
Fluorescent Antibody assay microscopy is typically used to detect antibodies against both 
phase II and phase I antigens [68]. An increased titer against phase II antigen is more 
indicative of an acute infection, while the presence of increased titers against both phase I 
and phase II antigens can indicate the occurrence of chronic illness [30, 56, 57, 65-68]. 
Previous treatment of acute Q fever used antibiotics such as tetracycline, cotrimoxazole, 
ofloxacin, and pefloxacin, or doxycycline for 14-21 days [2, 11, 69, 70]. Combination 
therapy with doxycycline and chloroquine or hydroxychloroquine for 14-21days is an 





Approximately five percent of C. burnetii infections manifest as chronic Q fever. 
The majority of patients developing chronic illness are over the age of 40. Chronic illness 
can develop anywhere from a month to several years following exposure. Individuals 
who develop chronic Q fever may have previously experienced acute Q fever or may 
have been asymptomatic following initial exposure [2, 71-75]. The most common clinical 
manifestation of chronic Q fever is valvular endocarditis. As many as 60-70% of chronic 
Q fever cases are characterized by endocarditis and the condition can be fatal if left 
untreated. Patients with underlying heart disease or previous cardiac valve defects 
account for 90% of endocarditis cases suggesting that damaged tissue provides a point of 
adhesion for C. burnetii infected cells. Chronic C. burnetii endocarditis typically affects 
aortic or mitral valves, although cases of Q fever endocarditis on prosthetic valves have 
also been reported [2, 56, 73-76]. Clinical symptoms of chronic Q fever endocarditis 
include low grade fever, cardiac valve dysfunction, fatigue, weakness, chills, anorexia, 
weight loss, and night sweats. Cardiomegaly, ventricular hypertrophy, and arrhythmia 
can be detected via chest x-rays and electrocardiography. Patients with Q fever 
endocarditis can have peripheral manifestations such as purpuric rash in mucosa and 
extremities, as well as digital clubbing [2, 56, 69, 71, 73, 75, 77-79]. Chronic hepatitis is 
often reported in association with Q fever endocarditis [2, 80]. If the illness goes 
untreated for long periods of time patients also suffer from splenomegaly and 





While endocarditis is the most common presentation of chronic Q fever, there are 
other prominent presentations. These include osteoarticular infections, pulmonary 
infections, chronic hepatitis, and chronic fatigue syndrome [2]. Although rare, chronic Q 
fever can present as vascular infections, which can be fatal [2]. Because C. burnetii 
colonizes the uterus, placenta, and mammary glands of infected pregnant women, Q fever 
has also been associated with intrauterine growth retardation, low birth weight, premature 
delivery, spontaneous abortion, and stillbirth [2, 65, 69]. 
Treatment of chronic Q fever is typically doxycycline and hydroxychloroquine for 
18 to 36 months. Because of the use of hydroxychloroquine, patients require regular eye 
examinations to monitor for light sensitivity development [2, 5, 11, 12, 70]. Pregnant 
women are not treated with doxycycline and chloroquine due to the risk of complications 
and are instead treated with cotrimoxazole [69].  
Vaccine History 
 C. burnetii is environmentally stable, typically acquired through an aerosol route, 
has an infectious dose of 1-10 organisms, and has been weaponized in the past [55]. 
These factors drove C. burnetii to be classified as a Class B Select agent by the Centers 
for Disease control [10]. This classification makes preventative measures against C. 
burnetii desirable. Preventative measures would include vaccination of both humans and 
animals, since ruminant livestock are a common reservoir of the organism [2, 11]. 
Experimental vaccines prepared from both virulent (phase I) and avirulent (phase II) 
organisms over several decades [81-84] have demonstrated that formalin-inactivated 




higher antibody titers than phase II C. burnetii in vaccinated guinea pigs [85].  
Vaccination of cattle provided protection against C. burnetii induced abortion, low fetal 
birth weight, and infertility, but did not eradicate C. burnetii in cattle that had been 
previously infected with the organism [2, 11]. A vaccine created in Europe that contained 
a mixture of C. burnetii and Chlamydia psittaci was also found to be effective against 
fertility issues in cattle and goats [2, 83, 86], however, humans in contact with these goats 
still reported developing C. burnetii infections. The results of animal vaccinations have 
been inconsistent, so animals are not currently being routinely vaccinated [2, 86].  
 For Q fever prevention in humans, there are three different types of vaccines 
currently available. The first is a Q fever vaccine called Q-Vax, and is prepared from 
formalin-inactivated Phase I C. burnetii Henzerling strain, that is currently only available  
in Australia [2, 11-13]. This vaccine has been found to be highly protective but causes a 
delayed-type hypersensitivity (DTH) response when inoculated into individuals with 
prior C. burnetii exposure [14]. Early vaccines given to laboratory workers in the 1940s 
and 1950s also resulted in a DTH response [13]. Due to this reaction, all individuals must 
receive a skin test for reactivity prior to receiving the vaccination. The second, in the US, 
is an Investigational New Drug (IND) that is also phase I formalin-inactivated C. burnetii 
Henzerling strain but is not commercially available. The third is a soluble 
lipopolysaccharide (LPS)-protein complex chemovaccine that is extracted form phase I 





 A chloroform-methanol pretreatment of phase I C. burnetii has been shown to 
reduce the DTH response seen in whole-cell formalin-inactivated C. burnetii vaccines, 
but it also reduces the level of protection [2, 88]. Individuals who are livestock handlers, 
animal product processors, veterinarians, or work in laboratories with phase I C. burnetii 
are highly recommended to be vaccinated [2, 11, 89, 90]. Research to find a safe and 
effective Q fever vaccine that does not require skin testing prior to administration 
remains an ongoing effort.  
 
Bacterial Life Cycle 
 Biphasic Life Cycle 
 C. burnetii is an obligate intracellular organism that is a Gram-negative 
pleomorphic coccobacillus. It has a biphasic life cycle with two distinct morphological 
forms, the small cell variant (SCV) and large cell variant (LCV) [6, 91]. The life cycle is 
summarized in Figure 2. The SCV is environmentally stable and metabolically inactive, 
measuring 0.2 to 0.5 um in length [6, 7, 91]. It has a thickened peptidoglycan layer, 
which has been measured to be from 13 to 21 nm in thickness. The SCV can persist in the 
environment for long periods of time and is resistant to several chemical and physical 
treatments. Analysis of peptidoglycan content indicates the peptidoglycan protein 
complex increases by approximately 30% as the organism transitions from its LCV to 
SCV forms [7, 8, 92]. This contributes to the environmental stability and makes SCVs 
less sensitive to desiccation, osmotic shock, ultraviolet (UV) light, sonication, and 




 In nature, the SCV that is thought to typically initiate infection following the 
inhalation of bacteria containing particles. After uptake of an SCV by an alveolar 
macrophage in the lung, the bacterium enters the host cells endocytic pathway, and ends 
up in a modified late endosome, with both early and late endosome markers, termed the 
parasitophorus vacuole (PV) [93]. Within the PV C. burnetii transitions from SCV to 
LCV, though the exact combination of signals or proteins that initiate this change are 
unknown [94]. This transition from SCV to LCV occurs during a growth lag phase of 
approximately 24-48 hours [95] after which the LCV enters logarithmic growth. The 
LCV has a thinner peptidoglycan layer than the SCV form as approximately 6.5 to 8 nm 
spans the peptidoglycan as well as the membranes and periplasmic space. The cell wall of 
an LCV is that of a typical Gram-negative cell, though they stain Gram variable [6, 7, 
91]. The transition from SCV to LCV initiates the exponential growth phase where the 
LCVs replicate at a doubling time of approximately 12.4 hours during growth within the 
host cell [95]. At approximately 6 days post infection, the bacteria enter a stationary 






Figure 2. Intracellular Life Cycle of C. burnetii. The environmentally stable 
SCV infects a host cell and enters a parasitophorus vacuole via the endosomal pathway 
where it transitions to the replicative LCV. Prior to host cell lysis C. burnetii transitions 




 In nature, C. burnetii is an obligate intracellular organism. When isolated from 
animals in nature or in the laboratory it is virulent and noted for causing disease [8, 42]. 
When virulent C. burnetii is grown in a laboratory setting in embryonated eggs, tissue 
culture, or ACCM for an extended period of time, bacteria within the population undergo 




organisms are referred to as “phase I” and after undergoing the phase change this 
avirulent form is referred to as “phase II” [8, 42]. The primary phenotypic difference 
between phase I and phase II C. burnetii isolates is lipopolysaccharide (LPS) length. The 
phase I, or virulent, C. burnetii produce a full-length LPS. Phase II C. burnetii possess a 
severely truncated LPS [8, 42]. When animals are inoculated with clonal isolates of phase 
II bacteria, they are injected into animals it does not cause disease [21]. 
The best characterized mutation that led to this attenuated virulence is caused by a 
deletion of 26 kb from the parent C. burnetii Nine Mile isolate within the chromosomal 
region associated with synthesis of the O-antigen of LPS [8, 24, 96-98]. There are three 
different LPS chemotypes of C. burnetii that have been reported [24]; Phase I, with full 
length LPS, Phase II LPS made up of lipid A and some of the core sugars, with the O-
antigen sugars are absent [8, 24, 96], and an additional LPS variant named Nine Mile 
Crazy (NMC) that has an LPS of intermediate in length, that demonstrates intermediate 
virulence. Interestingly, while the phase II deletion results in a more profound truncation 
than NMC, NMC has a larger chromosomal deletion, indicating that multiple factors may 
be involved [99]. 
While phase transition has been observed in multiple C. burnetii strains the 
classic Nine Mile strain, first isolated in Montana has been the best characterized. In 
addition, the C. burnetii Nine Mile phase II (NMII) isolate that is used throughout the 
world was clonally purified and represents the only C. burnetii strain that can be used 
outside of BSL3 containment. The phase II truncation of LPS in C. burnetii NMII has 
long been the attribute associated with its avirulence [99]. In addition, the change in 




tissue culture cells at a higher rate. However, after entering a cultured host cell, both C. 
burnetii NMI and NMII traffic, survive, replicate, and interact with the host cell from 
within the PV their replication within the host cell PV in a phenotypically 
indistinguishable manner [8, 21, 100-102]. These virtually identical intracellular 
interactions have made C. burnetii NMII an exceptional model with which to conduct 
host cell-pathogen molecular interaction research. 
Antibody titers of IgG to phase II antigens are higher in an acute infection, while 
chronic infection produce a higher titer against phase I antigen [2, 101, 103-105]. Phase 
II C. burnetii is more susceptible to the membrane attack complex of the complement 
system [106]. In addition, the full length LPS of phase I C. burnetii inhibits antibodies 
from binding to the bacterial surface proteins while also preventing C. burnetii from 
being detected by Toll like receptors (TLRs)  and blocking interaction with the CR3 
receptor in dendritic cells and macrophages [100, 107]. Combined, these findings clearly 
suggest that LPS is closely tied to the ability of C. burnetii to cause disease [24, 96, 107]. 
 
Type IVB Secretion System 
As C. burnetii is an obligate intracellular bacterium, secretion of virulence 
determinants into the host cell is crucial. The Type 4 Secretion Systems (T4SS) are a 
major virulence determinant that enables a number of pathogenic bacteria to deliver 
effector proteins into their host cell [108, 109]. There are two genetically distinct T4SSs 
that have been associated with bacterial virulence, the T4A and T4B Secretion Systems 




extensively in Agrobacterium tumefaciens [111]. The system is also found in 
Helicobacter pylori [112], Bordetella pertussis [113], Anaplasma spp. [114], Bartonella 
henslae [115], Brucella spp. [116], and Rickettsia spp. [117]. The known T4BSSs possess 
between 20-26 proteins and have been identified in fewer organisms. There are three 
bacteria, Rickettsia grylli, Legionella pneumophila, and C. burnetii, that are known to 
possess a functional T4BSS [118]. Coxiella burnetii utilizes a Type IVB Secretion 
System (T4BSS), that is a requirement for survival and growth in host cells, and has little 
homology to the T4ASS [119] The L. pneumophila T4BSS is by far the best 
characterized. Research investigating the genes involved in the intracellular survival and 
niche environment of L. pneumophila identified 20 genes that were necessary for 
survival, and 6 additional genes that are associated with  T4BSS function, but are not 
essential for intracellular survival [120-122]. These discoveries were made by two 
independent laboratories, one of which designated the genes dot (defect in organelle 
trafficking) [123] and the other designating them as icm (intracellular multiplication), 
thus the dual naming system in the T4BSS literature [124]. The L. pneumophila T4BSS 
has been shown to be capable of secreting at least 200 effector proteins into the host cell 
during infection [125].  
The first study to propose a loose structural model of the L. pneumophila T4BSS 
was reported in 2006[126]. The authors analyzed immunoblots of cellular fractions of the 
bacteria to identify the cellular location of Dot/Icm proteins [126, 127]. This study 
indicated that DotB, DotN, IcmQ, IcmR, IcmS, and IcmW were found in the cytoplasmic 
fraction, DotA, DotI, DotL, DotM, DotN, DotO, DotP, DotU and IcmF in the inner 




DotG, DotH, and DotK in the outer membrane fraction [126]. The immunoblots were 
unable to determine the location of DotE, DotJ, DotV, IcmT, and IcmV, which were 
previously predicted to be outer membrane proteins  based on  Kyte-Doolittle 
hydrophobicity plots [128]. Protein-protein analysis has suggested that DotC, DotD, 
DotF, DotG, and DotH interact to form a subcomplex that transverses the cell wall [126, 
129]. Additionally, DotL, DotM, and DotN are predicted to form a subcomplex at the 
inner membrane along with cytoplasmic proteins IcmS and IcmW [130]. The T4BSS has 
limited homology to other secretion systems, including the T4ASS, and a complete 
understanding of its molecular structure and function within the bacteria cell envelope 
does not exist. 
A current model of the T4BSS is depicted and summarized in Figure 3 [131]. The 
C. burnetii genome has 23 of the 26 T4BSS genes found in L. pneumophila, lacking 
homologs to the chaperone protein IcmR and predicted inner membrane proteins DotJ 
and DotV [119, 132, 133]. Studies have demonstrated that C. burnetii T4BSS genes are 
expressed early in infection [134] and that the T4BSS itself appears localized on the 
pole(s) of the bacteria during infection of host cells [135]. Several T4BSS proteins have 
been confirmed as being required for intracellular replication. Mutations of DotI [136] 
and IcmD [137] resulted in a loss of intracellular localization. Targeted deletion of dotA 
and dotB showed these genes to also be essential for intracellular growth [138]. 
Interestingly, C. burnetii T4BSS mutants have been shown to  be able to replicate within 
a PV if infections were established in combination with a wild-type C. burnetii [137]. 




functional T4BSS, but that niche development and subsequent bacterial growth does 
[136, 139].  
There are currently 62 known bacterial proteins that are delivered into the host 
cell by the C. burnetii T4BSS [136, 140-143]. Most of these effector proteins contain 
eukaryotic motifs, including coiled-coil domains, GTPase domains, ankyrin repeats, 
leucine rich repeats, and multiple kinases and phosphatases [136, 144, 145]. These 
eukaryotic motifs are thought to be required for interaction with host cell proteins via 
protein-protein interactions or regulation of host cell signal transduction pathways [146, 
147]. Despite the high degree of T4BSS structural protein homology, C. burnetii only 
encodes six homologs to effector proteins found in L. pneumophila [136, 143]. This is 
likely due to differences in their host environments, the vacuolar niche they require for 
survival and replication and could even influence the differences in the clinical outcomes 







Figure 3. Model of the Type 4B Secretion System. T4BSS structural model showing 
the proposed locations of the Dot/Icm proteins. It is hypothesized that the C. burnetii 






INTRANASAL IMMUNIZATION WITH WHOLE-CELL FIXED COXIELLA 






Coxiella burnetii is an obligate intracellular bacterial pathogen that causes Q fever. 
The debilitating acute form of the disease is characterized by headache, fever, photophobia, 
and pneumonia while chronic disease is often associated with valvular endocarditis and 
hepatitis.  C. burnetii is environmentally stable, has a low infectious dose, is transmitted by 
aerosol, and was weaponized in the past.  While this pathogen is controlled in the general 
population by pasteurization, it is on the CDC’s select agent list because of its ability to 
cause significant morbidity.  Studies have shown that intramuscular, sub-cutaneous, and 
intraperitoneal administration of whole-cell formalin fixed virulent (phase I) C. burnetii 
vaccine formulations is able to protect subjects from disease following subsequent C. 
burnetii phase I exposure. Our hypothesis was that a whole-cell formulation of killed C. 
burnetii would also be protective when inoculated intranasally. In an effort to determine if an 
intranasal route of immunization would elicit a protective immune response to C. burnetii 
infection, we used 106 whole-cell formalin fixed C. burnetii Nine Mile phase I (NMI) in 
combination with a double mutant of E. coli heat-labile enterotoxin adjuvant in a guinea pig 
model.  Booster immunizations followed at 14 and 28 days.  To determine a general measure 
of the humoral immune response, IgG titers were assayed by indirect fluorescent antibody 
microscopy using sera collected prior to, and at 14, 28, and 56 days following intranasal 
immunization.  C. burnetii NMI specific titers ranging from 4096 to 16384 were detected in 
day 56 sera, indicating a robust humoral response was elicited using intranasal immunization. 
In addition, immunized animals subsequently infected with virulent C. burnetii NMI did not 
develop significant clinical symptoms as measured by weight loss or fever. Studies defining 




antigen profile using this physiologically relevant exposure route will aid us in defining a 
protective response to this unusual aerosol acquired pathogen. 
 
Introduction 
Coxiella burnetii is an obligate intracellular pathogen and the causative agent of the 
zoonotic illness Q fever. The acute form of the disease is characterized by headache, fever, 
photophobia, and pneumonia. Chronic C. burnetii infection is often associated with 
endocarditis and hepatitis [2]. C. burnetii has a biphasic life cycle composed of two variants, 
the environmentally stable small cell variant (SCV) and the replicative large cell variant 
(LCV) [91]. Transmission occurs by aerosol and has a low infectious dose, with only 1-10 
organisms required for infection [9]. This pathogen is controlled in the general population by 
pasteurization but has been placed on the Center for Disease Control’s (CDC’s) select agent 
list because of its low infectious dose and ability to cause significant morbidity [10].  Recent 
advances in genomics, in vitro growth of C. burnetii, and the identification of bacterial 
factors required for pathogenesis offer the promise of identifying novel and effective targets 
for countermeasure development while advancing our understanding of the its basic biology. 
The one currently licensed vaccine, Q-Vax, is only available in Australia. This whole-
cell formalin fixed formulation is very effective but can cause a delayed type hypersensitivity 
response in individuals who have been previously exposed to C. burnetii. As a result, 
everyone must be screened for skin reactivity prior to vaccination [82, 88, 90]. In the U.S., a 
similarly formulated investigational new drug (IND) vaccine is held by USAMRIID for the 




required to administer these vaccines, however, make them impractical and overly expensive 
for broad use in military personnel and civilians. With the potential of C. burnetii as a 
weapon or bioterror agent as well as its endemic nature in many developing countries where 
troops are deployed, the need to understand the basic biology of a protective immune 
response and to develop an efficacious, safe vaccine against C. burnetii that can be 
administered to anyone is paramount. 
While it has been known for years that whole-cell formalin fixed C. burnetii provides 
protection against subsequent infection when administered sub-cutaneously, intramuscularly 
and even through intraperitoneal injection [2], there appears to be no history of whether this 
immunization would elicit protection when administered through an intranasal route, thus 
exposing the mucosa to antigen.  Given that C. burnetii is acquired through an aerosol route, 
we sought to determine if whole-cell formalin fixed C. burnetii NMI administered along with 
an adjuvant that has been used recently in rodent intranasal immunization studies [148] 
would protect guinea pigs against subsequent C. burnetii NMI challenge. 
 
Materials and Methods 
Bacterial Cultivation and Antigen Preparation: Virulent Coxiella burnetii Nine Mile 
Phase I RSA 439 (NMI) was propagated in African green monkey kidney (Vero) cells in 
RPMI 1640 medium, 5% fetal bovine serum (FBS) at 37°C in an atmosphere of 5% CO2, and 
the SCV form of the organism was isolated as described previously [95]. Purified C. burnetii 
NMI stocks were enumerated by counting fluorescent forming units (FFU) and stored at -




mM glutamic acid, pH 7.4). For antigen preparation, C. burnetii NMI was pelleted at 12,000 
g and fixed overnight in 4% formalin at room temperature. Bacteria were then washed in 
Phosphate Buffered Saline (PBS) (25 mM NaPO4, 150 mM NaCl, pH 7.4) buffer pH 7.4 and 
also heat inactivated for 30 minutes at 65°C. To demonstrate bacterial inactivation, aliquots 
were serially diluted and tested for the capacity to infect and replicate in Vero cells. Four 
days post infection, cells were methanol fixed and analyzed by indirect fluorescent antibody 
(IFA) microscopy and complete inactivation was confirmed. All C. burnetii NMI live growth 
and manipulations were performed in approved Biological Safety Level 3 (BSL3) laboratory 
settings. 
 
Animal Model and Sample/Data Collection: Female Hartley Guinea pigs (38-42 days 
old) were used throughout. Figure 4 outlines the timeline and procedures that occurred within 
the duplicate trials. Blood draws were performed via the cranial vena cava while weight and 
body temperature measurements were obtained by digital scale and rectal thermometer. All 
procedures followed protocols approved by the Oklahoma State University Institutional 






Figure 4. Fixed Whole-Cell Coxiella burnetii Intranasal Immunization of Guinea pig. 
Immunization, serum collection, C. burnetii NMI challenge, and weight/temperature 
observation(s) days post-challenge are indicated. The same format was used in both trial 1 
and 2. 
 
Immunization: Inactivated C. burnetii Nine Mile phase I (termed ΔCbI) was diluted in 
PBS with Double Mutant Lethal Toxin (DmLT) adjuvant (kindly provided by Dr. John 
Clements, Tulane University) such that 100 l contained 106 FFU equivalent of C. burnetii 
NMI in ΔCbI form and 2.5 g DmLT. A 100 l aliquot of antigen mix was administered to 
anesthetized guinea pigs (n=5) intranasally via a 1-inch flexible catheter inserted into the 
nasal canal to achieve deep delivery of the antigen mixture. Animals were given identical 
booster immunizations at 14 and 28 days following the primary immunization (see Figure 4). 
Control animals (2 groups of n=5) received sterile PBS mock intranasal immunizations. 
 
Coxiella burnetii NMI Challenge of Immunized Guinea pigs: Live, virulent C. 




in a volume of 200l PBS to control and standardize the infectious dose.  Intraperitoneal 
challenge in a guinea pig model is a well-controlled and established means of C. burnetii 
infection [149, 150]. The ΔCbI and one of the PBS immunized groups (mock-immunized 
controls) received the C. burnetii NMI challenge. The other PBS group received sterile PBS 
IP as a non-challenged control. All animals were monitored daily for weight, temperature, 
and behavior for a period of 14 days.  A pain and distress scoring system (Table 1) was used 
to determine when animals were under significant stress and required euthanasia [151]. 
 
Indirect Fluorescent Antibody Microscopy: Serum was separated from whole blood 
by centrifugation at 500 g for 5 minutes and subjected to IFA analysis to determine specific 
IgG maximum-inverse titer.  Gamma irradiation inactivated C. burnetii NMI (kind gift from 
Dr. Robert Massung, CDC) and the avirulent C. burnetii Nine Mile phase II (NMII) strain 
were applied to 16-well microscopy slides, air dried, then heat and acetone fixed for use as 
capture antigen. Two-fold serial dilutions of the Guinea pig sera was used as primary 
antibody and Alexa-488 goat anti-guinea pig heavy chain IgG (Molecular Probes, Eugene, 
OR) was used as secondary antibody. Slides were observed at 400X magnification using a 
















Intranasal Immunization Protects Against C. burnetii NMI Induction of Severe Fever.  
As part of the scoring system used to monitor the pain and distress of the guinea pigs, 
temperatures were recorded daily (Figure 5). In both trials all mock immunized and mock 
challenged animals did not record higher temperatures. The animals who received the CbI 
immunization and were challenged with live virulent C. burnetii NMI showed a transient 
fever, but all began to recover around day 4 following challenge. In trial 1 all of the mock 
immunized and virulent challenged guinea pigs continued to show an increase in temperature 
until all were euthanized. In trial 2 all showed an increase in fever until all but one was 
euthanized. The guinea pig in trial 2 that was not euthanized eventually recovered from the 
fever. 
 
Intranasal Immunization Ameliorates Weight Loss Following C. burnetii Challenge.  
Following challenge with C. burnetii NMI weights were monitored daily and percent 
weight change was recorded (Figure 6). The mock immunized and mock challenged guinea 
pigs did not show a percent loss following the mock challenge. The guinea pigs that received 
the ΔCbI immunization showed transient weight loss for a few days following challenge in 
both trials. After 4 days their weights began to trend back upwards. In trial one the guinea 
pigs who were mock immunized and received the virulent challenge lost weight until they 
were all euthanized at day 6. In trial 2 they lost weight in the beginning. The one guinea pig 






Figure 5. Temperatures of Guinea Pigs Immunized Intranasally with ΔCbI and 
Challenged IP 56 Days Later with Live C. burnetii NMI. The mean temperatures of 
immunized and control groups were compared over 14-days post-challenge. Two identical 
trials were performed. Each having an immunized group challenged with C. burnetii NMI 
(ΔCbI imm+Cb challenge), a mock immunized group challenged with C. burnetii NMI 
(Mock imm+Cb challenge), and a mock immunized group challenged with PBS (Mock 
imm+PBS challenge).   A – Trial 1. B – Trial 2.  Red arrow indicates the point at which only 
one Guinea pig of a group survived. * p value =0.001, unpaired, two-tailed student t-test 







Figure 6. Body Weight Changes (% total) of Guinea Pigs Immunized Intranasally with 
ΔCbI and Challenged IP 56 Days Later with Live C. burnetii NMI. The mean % changes 
in body weight of immunized and control groups were compared over 14-days post-
challenge. Two identical trials were performed. Each having an immunized group challenged 
with C. burnetii NMI (ΔCbI imm+Cb challenge), a mock immunized group challenged with 
C. burnetii NMI (Mock imm+Cb challenge), and a mock immunized group challenged with 
PBS (Mock imm+PBS challenge).   A – Trial 1. B – Trial 2.  Red arrow indicates the point at 
which only one guinea pig of a group survived. * p value =0.0430, unpaired, two-tailed 
Student t-test (Mean ΔCbI imm + Cb v. Mock imm + Cb). 
 
 
Intranasal Immunization Increases Guinea Pig Survival Following C. burnetii NMI 
Challenge. Following challenge with virulent C. burnetii NMI, all guinea pigs were 
monitored daily and scored based on a pain and distress scoring system (Table 1). When the 
pain and distress score was 0.5 or higher the observations were increased to twice daily. If 




all guinea pigs who received a mock PBS immunization and PBS challenge survived the 
study. All guinea pigs who received the ΔCbI immunization and were challenged with live C. 
burnetii NMI also survived in both trials (Figure 7). In trial 1 all of the Guinea pigs who 
received the mock PBS immunization and were later challenged with virulent C. burnetii 
NMI were all euthanized by 6 days following the challenge. In trial 2, one Guinea pig that 
received the mock immunization and virulent challenge was not euthanized. All others were 
euthanized by 7 days post challenge. 
 
Intranasal Immunization Elicits Anti-C. burnetii Antibodies. 
Serum was collected from the guinea pigs prior to immunization and at 14, 28, and 56 
days post immunization. Serial dilutions of this sera were used as primary antibody on slides 
that contained either fixed whole C. burnetti NMI, or C. burnetti NMII, as antigen. Pre-bleed 
sera and the sera of the mock immunized guinea pigs had an antibody titer <64 and were 
considered non-reactive (Table 2). The sera from 14 days post-immunization demonstrated a 
higher antibody titer to C. burnetti NMII than C. burnetti NMI. The 28-day antibody titer to 
C. burnetti NMI had increased to a point where it was similar to C. burnetti NMII. The 56-
day sera had a higher titer to C. burnetii NMI than at 28 days and was similar to or higher 
than the C. burnetti NMII titers, which has historically been considered indicative of a more 
chronic infection [152, 153]. All guinea pigs immunized with CbI had positive antibody 







Figure 7. Survival of Guinea Pigs Following IP Challenge with C. burnetii NMI After 
Previous Intranasal Immunization With ΔCbI.  Immunized and control groups were 
compared in separate identical trials. Ɨ – Nonreactive (NR), indicates the antibody titer was < 
64. * - CbI, whole-fixed C. burnetii Nine Mile Phase I was used as antigen ** - CbII, whole-






Table 2.  Trial 1 guinea pig reciprocal antibody titer following ∆CbI or PBS intranasal 
immunization 
 
Ɨ – NR, Nonreactive and indicates the antibody titer was ≤ 64. 
* - CbI, Nine Mile Phase I C. burnetii was used as antigen 






The goal of this study was to evaluate whether intranasal immunization produces a 
protective response to C. burnetii challenge. Guinea pigs were immunized intranasally with 
ΔCbI + DmLT. At day 56 post initial immunization the animals were challenged with live 
virulent C. burnetii NMI through IP injection to control and standardize the infectious dose 
delivered [149, 150] (see Figure 4).  Temperature (Figure 5), percent change in body weight 
(Figure 6) and percent survival (Figure 7) were monitored for 14 days post-challenge. In 
comparing these parameters for ΔCbI and mock immunized animals (both challenged and 
mock challenged), it was observed that ΔCbI immunized animals had a transient (≈4 day) 
increase in body temperature following challenge that then returned to control levels while 
mock immunized animals had elevated body temperatures at a level that contributed to their 
euthanization (Table 1).  Interestingly, one mock-immunized animal that was challenged in 
Trial 2 did not develop as high of an initial temperature and returned to normal body 
temperature day 8 post challenge. Measurements of percent body change in weight indicated 
trends similar to that of the body temperature measurements in the immunized and 
challenged guinea pigs. The ΔCbI immunized animals had a transient (≈4 day) decrease in 
body weight, after which time they began to gain weight again. Mock immunized animals 
that were challenged lost significant weight (Figure 6).  The one animal that survived 
challenge in Trial 2 also began to recover body weight after day 4. All other animals within 
that group had been euthanized by day 6, thus the survivor altered the weight data averages 
for this group. Survival analysis (Figure 7) clearly demonstrates the protective effect 
provided by ΔCbI intranasal immunization.  All of the ΔCbI immunized animals survived 




burnetii NMI required euthanization. It is unclear why the one animal in Trial 2 did not have 
as significant of symptoms post-challenge. It may have been a technical anomaly or simply 
the variability in the animal's ability to cope with infection.  
Studies along with the existing Q-Vax and IND vaccines have clearly shown that 
intramuscular, sub-cutaneous, and intraperitoneal administration of whole-cell formalin fixed 
virulent (phase I) C. burnetii strains are able to protect subjects from disease following 
subsequent C. burnetii phase I exposure [2]. However, discovery of the protective epitopes 
generated from these immunizations has remained elusive.  In an effort to determine if an 
intranasal route of immunization might elicit a protective immune response to C. burnetii 
infection, we used 106 whole-cell formalin fixed C. burnetii NMI in combination with DmLT 
adjuvant, as it has previously been used in intranasal vaccine studies [148]. The use of the 
intranasal immunization route places antigen(s) in contact with the mucosal immune system, 
which is likely to generate mucosal, humoral and cell mediated immune responses.  In 
addition, this route may generate immunity through epitopes not recognized by more 
traditional immunization routes [154]. Previous studies in sensitization by C. burnetii 
immunization indicate the potential for less reactivity when the immunization is delivered 
intranasally [150]. Further studies of the hypersensitivity response, minimal immunization 
schedule, alternate adjuvants and the characterization of the immune response elicited 










PROTEIN CHANGES ASSOCIATED WITH DECREASED HOST CELL 








Coxiella burnetii is an obligate intracellular bacterium in nature and the causative 
agent of the zoonotic illness Q fever [2, 12, 15, 131, 155-157]. Upon host cell entry, the C. 
burnetii containing vacuole follows the endocytic pathway, ultimately resembling an altered 
late endocytic vacuole that is termed the parasitophorus vacuole (PV) [6, 8, 15]. From within 
this vacuole C. burnetii utilizes a Type IVB Secretion System (T4BSS) to deliver effector 
proteins into the host cell, allowing for survival and pathogenesis [6, 8, 15, 131, 132].  
Given its obligate intracellular nature, early C. burnetii studies were conducted by 
maintaining the bacterium through serial passages that required the inoculation of a healthy 
guinea pig with the blood or minced spleen of an infected guinea pig [1, 2, 16, 17]. In 1939 it 
was discovered that C. burnetii could be cultivated in embryonated chicken eggs, creating a 
more efficient and standardized means to propagate the organism [17]. Infected yolk sacs 
could be harvested to produce far greater numbers of C. burnetii for subsequent studies [39].  
Later, the development and increased usage of eukaryotic tissue culture methods further 
improved the ability to study C. burnetii in more defined techniques as the organism readily 
infects a multitude of culture cell types [18, 95]. Further advances were made when a 
metabolism supporting media was developed in 1981that allowed for some short-term 
physiologic studies, however it did not support C. burnetii replication [48]. In the 2000’s this 
metabolic media was used as a starting point from which to develop a fully cell free growth 
media for C. burnetii [19].  In a landmark development within C. burnetii research, the first 
axenic growth media was developed and referred to as Acidified Citrate Cysteine Media 
(ACCM) [19]. Further improvements to ACCM have been made and include the removal of 




158], and finally a fully defined media, ACCM-D, which further improved growth while 
more closely replicating the bi-phasic life cycle of C. burnetii that is observed within infected 
cells [50, 159].  
Virulent strains of C. burnetii are referred to as phase I C. burnetii. When phase I C. 
burnetii are grown continually in eggs, tissue culture, or ACCM, bacteria within the cultures 
develop chromosomal mutations that lead to a change from phase I to what is called phase II 
C. burnetii [20, 98, 160, 161]. These chromosomal deletions result in a severe truncation of 
the bacteria’s lipopolysaccharide (LPS), causing a subsequent loss of virulence in animal 
models of infection. These changes were first observed in the original virulent C. burnetii 
Nine Mile isolate (phase I, NMI) after years of passages in embryonated eggs [20]. The 
avirulent phase II C. burnetii Nine Mile (NMII) clonal isolate RSA 493 was ultimately 
purified from these cultures [162]. This C. burnetii NMII strain is recognized as an 
exceptional model of C. burnetii-host cell molecular interactions as it demonstrates 
intracellular interactions that appear identical to those of the phase I parent strain within 
tissue culture infections [101, 107, 163]. The genetic mutation that is responsible for the loss 
of the LPS O-antigen has been frequently noted in C. burnetii organisms passaged in a 
laboratory environment [20, 98, 160, 161]. However, beyond this phase change, it is unclear 
what pathogen systems and/or genes may change when the environmental stresses found 
within a eukaryotic host cell are removed. 
Here, we hypothesize that C. burnetii NMI changes its gene expression within the 
first few passages upon transition from intracellular to axenic media growth. We used a 




are no longer required for intracellular survival as the organism is grown continually in 
axenic media.  
 
Materials and Methods 
Bacterial Cultivation 
C. burnetii Nine Mile phase II (NMII) was cultivated in HeLa cells and the SCV form 
was collected and stored in SPG buffer (0.7 M sucrose, 3.7 mM KH2PO4, 6.0mM K2HPO4, 
0.15 M KCl, 5.0 mM glutamic acid, pH 7.4) as previously described [95]. Cell propagated C. 
burnetii was used to inoculate 1X ACCM-D (Sunrise Science Products, San Diego, CA) [50, 
52] with 106 genome equivalents per mL and grown in a Panasonic O2/CO2 Incubator for 7 
days at 5% O2 and 5% CO2 at 37C. Subsequent passages were created by 10-3 dilution into 
freshly prepared ACCM-D and repeated incubation.  This methodology was used continually 
on a 7-day interval to create subsequent passages, as shown in Figure 8. 
 
Axenic Media Preparation 
The 1X ACCM-D media was prepared using 2X ACCM-D (-glucose) powder 
(Sunrise Science Products) and Microbial Cell Culture Grade Water (Fisher BioReagents) 
following the manufacturer’s instructions. After stirring the media for at least 2 hours (longer 
for larger volumes), the pH was adjusted to 4.75 using NaOH or HCl as appropriate. The pH 
stability of the media is crucial for subsequent uses. The media was then filter sterilized using 




volume being generated. ACCM-D agar plates were prepared using a 2X media preparation 
of ACCM-D combined with equal volumes of 1.0% agarose (Invitrogen UltraPureTM) 














Determination of Genome Equivalents 
Genomic DNA was isolated from samples passaged in ACCM-D by heating 100 uL 
of the frozen passage sample to 85 C for 10 minutes in 400 uL nuclease free water. These 
DNA samples were diluted 1:10 and 1 uL of the dilutions were added to SYBR Green Master 
Mix (Applied Biosystems). Primers to com1 were used were (forward, 5’-
GCACTATTTTTAGCCGGAACCTT – 3’ reverse, 5’ – 
TTGAGGAGAAAAACTGGATTGAGA – 3’). Genome standards of 106, 105,104, and 103 
copies were used to create a standard curve. Real-time PCR was performed on an Eppendorf 
realplex2 Mastercycler and analyzed using the Eppendorf Mastercycler realplex 
software[134]. 
 
In Vitro Bacterial Enumeration  
To determine colony forming units of ACCM-D cultured C. burnetii NMII, ACCM-D 
agar was initially poured into 6-well tissue culture plates and cooled for 2 hours. Then, 
various C. burnetii NMII passages were diluted in 1X ACCM-D to normalize samples by the 
number of genomes (genome equivalents) per volume.  Subsequent 10-1 serial dilutions were 
prepared and 10 uL of each dilution sample was spread plated onto the appropriate ACCM-D 
agar wells. The inoculated plates were then incubated in a Panasonic O2/CO2 Tri-gas 
Incubator at 5% O2 and 5% CO2 at 37C. After 14 days the plates were removed, the colonies 
were counted, and calculations made to determine the number of in vitro viable bacteria in 





Host Cell Infectivity and Growth 
To determine the infectivity of serially passaged ACCM-D cultured C. burnetii NMII, 
HeLa cells were seeded onto 96 well culture plates at a density of 104 in RPMI containing 
2% FBS 16 hours prior to infection to allow for cellular adherence. Serially passaged C. 
burnetii NMII samples were diluted in RPMI to normalize the number of genomes per 
volume. Serial dilutions were performed (10-1 to 10-8) and 50 uL of each bacterial dilution 
was inoculated onto the HeLa cell containing wells and centrifuged at 600Xg for 15 minutes 
at room temperature [41]. Immediately following centrifugation, the inoculating media was 
replaced with 200 uL of fresh RPMI containing 2% FBS. The plates were incubated at 37C 
and 5% CO2. After 72 hours the wells were fixed with ice-cold methanol for 10 minutes in 
preparation for Indirect Fluorescent Antibody microscopy analysis as previously published 
[41]. Briefly, C. burnetii was stained using rabbit whole anti-C. burnetii NMII antibody 
diluted 1:1000 in PBS containing 3% BSA as a blocking agent. Primary antibodies were 
detected using Alexa Fluor 488 labeled goat anti-rabbit IgG antibodies diluted 1:1000 in PBS 
containing 3% BSA (Invitrogen). Total DNA was stained using 4’,6-diamidino-2-
pheylindole (DAPI) diluted 1:10000 in PBS containing 3% BSA (Molecular Probes) to 
illuminate host cell nuclei. The methanol fixed and stained cultures were visualized on a 
Nikon Eclipse TE2000-S and the number of maturing PVs were counted and calculations 
performed to ascertain the number of fluorescent forming units, which indicates the 







A 5 mL aliquot of each C. burnetii ACCM-D grown passage sample was centrifuged, 
and the pellet was resuspended in 500 uL Laemmli buffer (BioRad). The protein samples and 
combined Dual Color and Chemiluminescent Western Standard ladders (BioRad) were 
separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to 
nitrocellulose membranes (Whatman) using a semi-dry transfer apparatus (BioRad) at 12 V 
for 75 minutes. Membranes were blocked for 1 hour in 5% non-fat powdered milk in PBS 
with 0.05% Tween-20 (PBS-T) and probed using rabbit anti-sera against either recombinant 
C. burnetii Com1 (diluted 1:10000) (for protein normalizations), DotA (diluted 1:5000) or 
IcmX (diluted 1:1000) in PBST containing 5% non-fat dry milk as a blocking agent [41]. 
Following overnight incubation, the membranes were washed three times using PBS-T for 10 
minutes. The membranes were then incubated using horse radish peroxidase (HRP) labeled 
goat anti-rabbit IgG (Cell Signaling) diluted 1:5000 in PBS-T containing 5% non-fat dry 
milk for one hour at room temperature. Washes were repeated, and the antibody labeled 
proteins were detected using SuperSignal West Pico Chemiluminescent Substrate (Pierce). 
Visualization and digital imaging were performed using a ProteinSimple FluorChemE 
imager. To ensure C. burnetii protein content of samples were equivalent, immunoblot 
analysis and C. burnetii total protein was normalized using rabbit anti-Com1 prior to 
immunoblot analysis of DotA and IcmX [41]. Relative protein quantitation analysis was 






Mass Spectrometry Analysis 
Cells were lysed in guanidine lysis buffer. Lysates were exchanged into urea, 
alkylated, and trypsinized using the FASP procedure [164].  Trypsinolytic peptides were 
further purified by solid phase extraction and injected onto an Acclaim Proteoprep C18 
nanocolumn (Thermo PN164642).  Columns were developed using a gradient of 3-28 percent 
water/acetonitrile formulated in 0.1% formic acid, developed over a period of 120 min at 250 
nL/min. Eluting peptides were ionized within a Nanospray Flex ion source (Thermo) and 
analyzed within a quadrupole-Orbitrap Fusion mass spectrometer (Thermo).  Precursor ions 
were analyzed in the Orbitrap sector at nominal resolution 120,000, followed by “Top 
Speed” data-dependent MS/MS scans using the ion routing multipole for fragmentation by 
higher energy collisional dissociation and fragment analysis within the ion trap sector.  The 
specific instrument settings are provided within the Supplement. 
MaxQuant v1.6.2.10 [165] was used to search instrument RAW files against a 
database 1,812 C. burnetii proteins downloaded from Uniprot on February 6, 2018.  Searches 
utilized default MaxQuant settings, supplemented with Gln cyclization to pyroglutamate as a 
variable modification and with the “match between runs” feature specified.  Protein 
quantifications were analyzed within the Perseus framework v1.6.7.0 [166] using LFQ 
protein intensities [167]. A total of three biological replicates were used and student’s t-test 
on log2 LFQ protein intensities were used to determine significance. Protein intensities were 







 Coxiella burnetii Infectivity Decreases Following Multiple Passages 
 Upon the anecdotal observation that serially passaged C. burnetii appeared to infect 
cultured cells less readily than cell derived bacterial stocks, we wanted to quantitatively 
assess whether this was the case. Using C. burnetii NMII serially passaged 1, 3, 5, and 10 
times in ACCM-D, we initiated infections of Hela cells with bacterial dilutions normalized 
by the number of genomes in each sample. When the number of fluorescence forming units 
(FFU) per sample were calculated, they revealed a decrease in the number of C. burnetii 
filled vacuoles in tissue culture cells as the bacteria from subsequent passages are analyzed, 
respectively, resulting in a nearly two-log decrease between Passages 1 and 10 (Figure 9A). 
This indicates that there are fewer bacteria per genome that are capable of initiating a typical 
infection following multiple passages.  
 
Coxiella burnetii Viability in Axenic Media Does Not Decrease Following Multiple Passages 
 We next wanted to determine if the decrease in infectivity of tissue culture cells was 
associated with a decrease in in vitro viability of the C. burnetii as measured by colony 
forming units on ACCM-D agar. To address this question, we plated dilutions of passages 1, 
3, 5, and 10 on ACCM-D agar plates and counted the colonies. Contrary to the decrease in 
infectious units (Figure 9A), the colony counts indicated that there was no significant change 
in viable bacteria relative to genomes as the organism is serially passaged (Figure 9B). This 
indicates that the number of live and replicative bacteria is not changing, and therefore not 


















Figure 9. Intracellular vs Axenic Growth Following Serial Passage of C. burnetii NMII 
Intracellular and axenic growth from 3 biological replicates of passaged ACCM growth A) 
FFU counts of infections of HeLa cells normalized by C. burnetii genomes from passages 1, 
3, 5, and 10. Significance is indicated. *p<0.001. B) CFU enumeration of passages 1, 3, 5, 
and 10 C. burnetii spread on ACCM-D plates normalized to genomes. No statistically 





Coxiella burnetii T4BSS Proteins Concentrations Decline Following Multiple Passages in 
Axenic Media  
In an effort to address a possible cause of this decrease in infectivity, we sought to 
characterize the expression of proteins from a known virulence mechanism, the C. burnetii 
T4BSS. It is well-established that a functional T4BSS is necessary for proper C. burnetii 
vacuole formation and growth of the organism [118, 137, 168]. DotA and IcmX are structural 
proteins of the C. burnetii T4BSS and key components required for its functioning [41, 137]. 
Immunoblot analysis of C. burnetii NMII passages 1, 3, 5, and 10 indicated that protein 
concentrations of both DotA and IcmX showed very little change in passages 1, 3, and 5. 
However, a significant decrease of both proteins is observed by passage 10 (Figure 10A). 
While the decrease in relative DotA concentration is greater than that of IcmX, Figure 10C 
clearly demonstrated that the expression of both was significantly reduced by passage 10. 
 To determine whether this was a transient decrease, or if the concentrations of either 
protein continued to change following continued serial passages. Immunoblot analysis was 
performed to include passages 15 and 20. These data clearly indicate that DotA and IcmX 
concentrations in passages 15 and 20 remained consistent with the decreased relative 
concentrations observed in passage 10 (Figure 10B). These data suggest that sometime after 
passage 5, the concentration of two T4BSS homologs that are crucial to PV development and 
C. burnetii survival and growth intracellularly decline and remain reduced during subsequent 





Figure 10. Relative Concentrations of C. burnetii DotA and IcmX in Passages 1-20.  
Immunoblot using primary antibody against DotA and IcmX, and the outer membrane 
protein Com1 as a total protein loading control. A) samples from passages 1, 3, 5, and 10. B) 
Bar graph demonstrating protein concentrations of DotA and IcmX relative to Com1 and 
percent change from passage 1 in passages 1, 3, 5, and 10 on three biological replicates. C) 
samples from passages 1, 3, 5, 10, 15, and 20. D) Bar graph demonstrating protein 
concentrations of DotA and IcmX relative to Com1 and percent change from passage 5 in 
passages 5, 10, 15, and 20 on three biological replicates. 
Mass Spectrometry Analysis Indicates Significant Proteomic Changes Occur in C. burnetii 
NMII During Continuous In vitro Growth 
Mass spectrometry analysis was performed on total protein samples of passages 1, 3, 
and 5 to determine the extent of global proteomic changes occurring during the early serial 




5 revealed several protein expression changes that occurred in these early passages (Figure 
11A-C). Proteins with a p-value of p<0.05and a log2 ratio of +/- 0.7 were considered to be 
significantly changed from the passage to which they were compared. The majority of 
detected protein changes occurred in passage 3 when compared to passage 1 (Figure 11A). 
Compared to passage 1, there were 109 proteins that were changed in passage 3. Of the 109 
proteins that changed, 82 increased in concentration while and the remaining 27 
demonstrated decreased concentrations relative to passage 1 (Figure 1D). When comparing 
passage 5 to passage 1 (Figure 1B), 48 proteins were found in passage 5 to have changed in 
concentration relative to passage 1. Of these, 20 proteins demonstrated increased 
concentrations and 28 decreased concentrations. When comparing the proteins that were 
changed in both passage 3 and passage 5 relative to passage 1, it was determined that 11 
proteins were increased in both passages, and 14 proteins were decreased in both (Figure 
11D). A comparison of the protein expression of passage 5 relative to that of passage 3, only 
4 proteins were found to demonstrate a significant change. Of these, 2 were increases in 
concentration. Interestingly, one of these was a guanyltransferease that was also increased in 
passage 5 when compared to passage 1, and the other was an uncharacterized protein that 
was only determined to be significantly changed between passages 3 and 5. The other 2 
proteins demonstrated decreased concentrations. One of these was a membrane protein and 
the other an enzyme predicted to have lyase activity. It also had a decreased concentration 
relative to passage 1 (see Appendix). 
 There were several different types of protein homologs whose concentration 
increased in passages 3 and 5 relative to that of passage 1. Proteins predicted to be involved 




were among those groups with several proteins increasing in concentration. There was also 
one protein (GrpE) predicted to be involved in protein folding, and 3 proteins predicted to be 
involved in antibiotic resistance (two multidrug resistance proteins and one beta-lactamase) 
with increased concentrations. Of particular interest given our host cell infectivity findings, 
the largest group of characterized proteins whose concentrations were decreased relative to 
passage 1, were six proteins predicted to be associated with host cell entry. Of these six 
proteins, two were decreased in both passage 3 and passage 5 when compared to passage 1, 
and the other four were decreased in passage 5 relative to passage 1 (Table 3). Additionally, 
there were hypothetical export proteins with reduced expression in both passage 3 and 
passage 5 relative to passage 1. There were twenty-three uncharacterized proteins identified 
to be significantly changed. Of these, four were decreased in both passage 3 and passage 5 
when compared to passage 1, four were decreased in passage 3 compared to passage 1, and 
one was decreased in passage 5 compared to passage 1. There were fifteen uncharacterized 
proteins that were increased; six in passage 3 compared to passage 1, three in passage 3 and 
passage 5 compared to passage 1, four in passage 5 compared to passage 1, and the one 
protein uncharacterized protein that was mentioned earlier to be increased in passage 5 when 
compared to passage 3 (see Appendix). When searching for known T4BSS effector proteins 
4 were found to be significantly changed. Of these 4 proteins, one was decreased while the 
other 3 were increased. This suggests that several protein changes are occurring in these early 
passages that may further the understanding of proteins necessary for host-cell infection 





Table 3: Proteins from Groups of Interest that were Found to be Either Increased or 
Decreased via Mass Spectrometry Analysis 
Gene Name Protein Group Up/Down Passages (-log p-value) Fold Change 
icmP IcmP T4BSS Up P1 vs P3 1.393569145 0.798053741 
icmG IcmG T4BSS Up P1 vs P5 1.864376676 0.800012589 
CBU_1244 
Multidrug 
resistance protein B 
Resistance Up P1 vs P3 1.522278754 1.618398666 
CBU_0797 
Multidrug 
resistance protein B 

























































































Figure 11. Analysis of C. burnetii Global Protein Content Changes in Passages 1, 3, and 
5. Volcano Plot of log2 transformed protein changes against -log of the p-value from t-test in 
A) passage 3 vs passage 1, B) passage 5 vs passage 1, and C) passage 5 vs passage 3. D) A 
Venn Diagram demonstrating the similarities and differences seen in protein level changes 
between passage 3 and passage 5 as compared to passage 1. Analysis was performed in 







 We hypothesized that repeated passages of C. burnetii in ACCM-D would result in a 
loss of infectivity due to gene expression changes. Propagation in ACCM-D gives C. burnetii 
NMII everything required for growth, yet without many of the obvious environmental 
stressors present in a eukaryotic host cell [52]. Given the history of phase transition that 
results in LPS truncation when virulent strains are serially grown in models lacking an 
immune system, we sought to determine if the reduced environmental stress present during 
ACCM-D growth would result in phenotypic and molecular changes within C. burnetii 
NMII, and to then begin to determine what those changes may be. Initiating our studies with 
C. burnetii NMII provided us the opportunity to look beyond LPS transition, since the isolate 
already has that phenotype, and instead look for other uncharacterized changes that may 
occur when the bacteria are not faced with the struggles of growing in the eukaryotic host 
cell environment. When the infectivity of bacteria passaged 1, 3, 5 and 10 times were 
compared, we observed an approximately 2-log decrease in passage 10 compared to passage 
1 (Figure 9A). In contrast, colony forming units for the same passages showed no significant 
differences in C. burnetii NMII viability (Figure 9B). Taken together, these data indicate that 
changes that are occurring during the first 10 passages that are contributing to a decrease in 
the organisms ability to infect and grow in eukaryotic host cells do not appear to have any 
effect on the viability of C. burnetii NMII while growing in ACCM-D.  
 In an effort to begin to determine some of the virulence mechanisms that may be 
involved in the reduction of infectivity, we looked at the expression of homologs of the C. 
burnetii T4BSS, a known virulence mechanism that is required for the formation of the 




structural proteins [118] and immunoblot analysis of these proteins indicate there is a 
decrease in protein concentrations by serial passage 10 (Figure 10). While DotA had a 
greater decrease than IcmX by passage 10, both of these crucial T4BSS proteins are 
significantly reduced in relative protein concentration relative to earlier passages. To 
determine whether this decrease was transient, we analyzed the protein concentrations of 
both in even later passages. Immunoblots clearly demonstrate that passages 15 and 20 had 
similar protein levels to passage 10 (Figure 10), remaining significantly lower than passages 
1,3,and 5. These data suggest that the loss or greatly reduced expression of a functional 
T4BSS may be one of the molecular changes resulting in a decrease in infectivity and/or PV 
development following serial passages of C. burnetii in axenic media.  
Mass spectrometry analysis of the first five passages indicate significant protein 
expression changes occurring in these early passages (Figure 11). Relative protein 
concentration reduction in host-cell entry proteins and hypothetical export proteins support 
our hypothesis that C. burnetii proteins no longer needed for growth within a host cell will 
decrease in these early passages. Interestingly, there were several proteins whose 
concentration increased that are predicted to be involved in membrane synthesis and 
structure, as well as ATP synthesis and metabolism. These protein groups and their 
involvement in these early passages are interesting findings that will lead to future 
investigation. There were also antibiotic resistance proteins whose concentrations increased. 
These data collectively indicate that several proteomic changes are occurring in these early 
passages that have an effect on the passaged bacteria’s ability to infect host cells, but do not 
result in a change in in vitro growth. This supports our hypothesis that molecular changes 




that these changes are responsible for a decrease in host cell infections. Determining why 
some of these protein changes are occurring in response to growth in axenic media could 
help further our understanding of C. burnetii virulence and infection. Future studies include 
comparing our immunoblot findings to passage-matched whole-cell mass spectrometry and 







SUMMARY REVIEW OF COXIELLA BURNETII INTRANASAL IMMUNIZATIONS 
















It is well established that whole cell killed virulent strains of C. burnetii can be used as 
vaccines, yet they have a myriad of unintended issues. They have been used intramuscularly, 
intraperitoneally, and subcutaneously to good effect. However, an intranasal route of 
immunization has never been characterized with regards to protection from C. burnetii challenge. 
We hypothesized that a whole cell killed formulation of phase I C. burnetii would also effectively 
immunize guinea pigs when administered intranasally. Intranasal immunization offers an 
alternative route that directly exposes the mucosa to the antigen. We tested our hypothesis using a 
formulation of whole-cell formalin fixed C. burnetii combined with the adjuvant DmLT, which 
has been used recently in other intranasal immunization studies [148]. We discovered that guinea 
pigs immunized with this formulation were protected when compared to those who received a 
mock immunization of PBS and DmLT. When challenged with live, virulent C. burnetii, those 
animals that had been immunized showed a modest, transient fever for approximately 4 days, but 
returned to normal temperature levels thereafter. In contrast, the guinea pigs who received a mock 
immunization had high fever until euthanization was required. The same proved true of weight 
loss. Those that were immunized with the killed C. burnetii experienced only modest transient 
weight loss, but soon recovered and regained weight. In the mock immunizations all but one 
animal continued losing weight until euthanization was required.  
Following mock immunization only one guinea pig out of ten did not meet the 
requirement for euthanization when challenged with virulent C. burnetii. Serum from guinea pigs 
that was drawn following immunization, but prior to challenge, indicated that significant titers of 
antibodies against both phase I and phase II C. burnetii were elicited. The goal of this analysis 
was to determine if the intranasal route of immunization was protective. We were able to 
demonstrate that the formulation of whole-cell formalin fixed C. burnetii with DmLT was able to 
protect guinea pigs against virulent C. burnetii challenge and that significant antibody titers 




broader characterization of the immune response including determining the immune cells and 
cytokines involved in the immune response and doing additional antibody titers to IgA to further 
characterize the mucosal immune response. Additional future studies would include 
immunization testing on animals with previous exposure to C. burnetii to determine the 
occurrence and severity of the hypersensitivity reaction in intranasal immunizations. 
The ability to grow C. burnetii in the absence of a host cell is a recent development. 
Previous laboratory growth outside of animals was performed in embryonated eggs and tissue 
culture. When grown in embryonated eggs, tissue culture, or ACCM, a well-documented phase 
transition occurs that results in the development of avirulent phase II C. burnetii. However, 
beyond this phase change, it is unknown what other molecular changes may occur when the 
stressors of life within a eukaryotic host cell are removed. We had noticed anecdotally that 
infections initiated with C. burnetii NMII that had been passaged multiple times in ACCM-D 
were not producing an infection level that was expected based on the number of genomes used to 
initiate the infection relative to infections initiated using host-cell derived bacterial stocks. We 
know that in nature C. burnetii is an obligate intracellular organism [1] and that the development 
of axenic media is a recent advancement in C. burnetii research [19]. While the phase change that 
occurs when C. burnetii is grown outside of an animal host is well understood relative to LPS 
transition [23-25], we do not know what other molecular changes may occur beyond LPS phase 
transition when the stressors of an intracellular environment are completely removed.  
We hypothesized that physiological changes would occur in the first several passages of 
phase II C. burnetii in ACCM-D resulting from protein expression modulation. To test this, C. 
burnetii NMII was isolated from tissue culture and used to inoculate ACCM-D, after which is 
was serially passaged weekly in a continuous manner. Within the first 10 passages a significant 
decrease in the number of vacuoles counted following the infection of tissue culture cells was 




assays showed no significant difference in the number of colony forming units when the bacteria 
were plated on ACCM-D agar. This indicates that there are changes in cellular infectivity 
occurring when intracellular stresses/signals are removed and C. burnetii is grown for several 
generation in cell-free axenic media.  
In order to begin elucidating what molecular changes may be contributing to the loss of 
infectivity, we began by looking at two proteins of the Type IVB Secretion System (T4BSS). The 
T4BSS is a known virulence mechanism required for productive host cell infection [2], and both 
DotA and IcmX are structural proteins of the T4BSS. When characterizing DotA and IcmX 
protein concentrations through the first 10 passages, we found that there were no significant 
differences between passages 1, 3 and 5, but by passage 10 there was a significant decrease in the 
amount of both proteins. The decrease in DotA was greater than that of IcmX, with DotA being 
virtually undetectable by immunoblot in passage 10. To determine if protein concentrations might 
change in later passages, and to ensure that the decrease in both proteins was not a transient 
change, we then analyzed the protein concentrations of passages 15 and 20. In both of these 
passages, DotA and IcmX protein concentrations were not significantly different from those in 
passage 10, suggesting that for these T4BSS homologs continuous ACCM-D growth 
downregulates the expression of proteins within this crucial virulence mechanism There were also 
several protein differences detected in the first 5 passages via mass spec analysis. Some of the 
proteins that were found to decrease were involved in host-cell entry and hypothetical export 
proteins. These changes suggest that our hypothesis that proteins that are necessary for host cell 
infection but may not be necessary for growth in axenic media and may be decreased within early 
passages may be supported. Interestingly, several proteins including some involved in the 
bacterial membrane, ATP synthesis, and antibiotic resistance were increased in these early 
passages. Studies to determine what, if any, effect these changes have on the bacterial cell could 




in membrane associated proteins and ATP synthesis could be due to an increase in cell size or 
replication time by doing growth curves or microscopy on the C. burnetii from these passages.  
Might these findings point to an increased capacity of membrane synthesis and ATP production 
as the bacteria ceases to compete with the host cell and increases its growth rate? Future studies 
are underway which include mass spectrometry analysis out to passage 10 in order to confirm the 
significant changes detected via immunoblot analysis and to determine whether other proteins are 
following the pattern of changing more significantly by passage 10. In addition, RNAseq analysis 
of passages paired to those analyzed by mass spectrometry is being prepared to determine 
whether these same gene expression changes are occurring at the transcriptional level. Further 
immunoblot analysis and C. burnetii mutants will be generated in the future to confirm and 
further characterize changes seen via mass spec and RNAseq data. In the future, longer term 
passages (> 20 passages) will  be analyzed via DNAseq analysis in an effort to identify mutations 
that occur in genes that are not essential for growth in axenic media but may be necessary for 
infection As we identify changes that occur during continuous  axenic media growth, it is our 
prediction that we will find mechanisms that are crucial to the intracellular lifestyle and 
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Antioxidant Down P1vP3 2.258087 -0.84859 
sdhE 




Up P1vP3 1.788635 1.38653 
sdhE 
FAD assembly factor 
SdhE 










CBU_1638 ATPase ATP Up P1vP3 1.576246 0.95437 
atpH 
ATP synthase subunit 
delta 
ATP Up P1vP3 1.797322 0.71135 
CBU_1458 Hypothetical ATPase ATP Up P1vP3 1.493799 0.77033 
CBU_2021 Hypothetical ATPase ATP Up P1vP3 1.698858 0.7794 
CBU_1087 ATP/GTP hydrolase ATP Up P1vP3 1.330101 0.83297 
CBU_1234 Hypothetical ATPase ATP Up P1vP3 1.694969 0.90506 
atpB 
ATP synthase subunit 
a 
ATP Up P1vP3 1.8757 2.92569 










ATP Up P1vP3 1.802325 2.56335 














Detox Down P1vP3 2.061924 -0.7345066 
CBU_0909 
Sua5/YciO/YrdC/Ywl
C family protein 


























DNA Up P1vP3 1.8926087 0.89229393 
recO 
DNA repair protein 
RecO 




DNA Up P1vP3 1.42651706 0.82139969 
ku 
Non-homologous end 
joining protein Ku 
DNA Down P1vP3 2.22760569 -1.6073532 
ku 
Non-homologous end 
joining protein Ku 





DNA Down P1vP3 1.75800637 -0.8281517 
scvA 
Protein ScvA - 



















































































Ion Binding Up P1vP3 2.48029613 0.8051281 
 80 
cyoB 
Cytochrome c oxidase 
polypeptide I 
Ion Binding Up P1vP3 1.34971199 1.00341225 








































Membrane Down P1vP3 1.44151615 -1.3545551 















Membrane Down P1vP5 1.99174502 -0.715395 
lapB 
Lipopolysaccharide 
assembly protein B 




































Membrane Up P1vP3 1.48709929 0.70412064 
CBU_0056 
Type I secretion outer 
membrane protein 





























Membrane Up P1vP3 1.35844306 1.51163864 
CBU_0519 
DedA family protein - 
cell membrane 


















Membrane Up P1vP3 2.31105585 2.49395561 









Metabolism Down P1vP3 2.56065209 -1.0362358 
CBU_1269 Acyl-CoA hydrolase Metabolism Up P1vP3 1.79312145 0.80471039 
CBU_0834 Methyltransferase Methylation Up P1vP3 1.42257144 1.1479969 
grpE Protein GrpE 
Protein 
Folding 






















30S ribosomal protein 
S12 
Ribosomal Down P1vP3 1.32190704 -1.2042046 
rplR 
50S ribosomal protein 
L18 





Ribosomal Up P1vP3 1.6661528 0.74196243 
rpmA 
50S ribosomal protein 
L27 




RNA small subunit 
methyltransferase B 
Ribosomal Up P1vP3 3.46153474 2.28874588 
sspA 
Stringent starvation 
protein A homolog 












icmP IcmP T4BSS Up P1vP3 1.39356914 0.79805374 
icmG IcmG T4BSS Up P1vP5 1.86437668 0.80001259 
CBU_1361 Rrf2 family protein 
Transcriptio
n 
























































Transporter Up P1vP3 1.8525572 2.04579163 








Transporter Up P1vP3 1.62436911 1.50629807 
CBU_1796 Amino acid permease Transporter Up P1vP3 2.03790276 1.52624512 
corB 
Magnesium and cobalt 
efflux protein 



















































































































































































a: (-log p-value) – significance of the associated protein 
b: Fold Change – amount of increase or decrease of the associated protein 
c: Gene – Gene identifier for the associated protein 
d: Protein – Protein Name 
e: Group – Assigned group based on protein function 
f: Up/Down – indicator of whether the protein was increased (up) or decreased (down) 
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